Diabetes Mellitus, microalbuminuria, glycocalyx, ACE-inhibitor
Conditions
Interventions
All included subjects will be randomly treated with either placebo or lisinopril 20 mg for two weeks, followed by a two week washout period. After the washout period, the subjects who received placebo
Sponsors
Academic Medical Center (AMC), Department of Internal Medicine
Eligibility
Inclusion criteria
Inclusion criteria: 1. Caucasian males 2. Diagnosis of type 1 diabetes according to ADA criteria 3. Urinary albumin/creatinin ratio <3,5 mg/mmol, without antiproteinuric treatment
Exclusion criteria
Exclusion criteria: 1. Hypertension as defined by systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg or use of antihypertensive drugs 2. Previous use of RAS inhibitor2 3. Smoking 4. Primary dyslipidemia’s 5. Use of statins during the six weeks before visit 1 6. Use of antioxidants in the two weeks prior to visit 1 7. Angioedema in medical history 8. Hypersensitivity to ACE inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of this study is the change in microvascular glycocalyx thickness after treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are changes in oxidative stress, inflammation, coagulation microalbuminuria and glomerular charge selectivity. | — |
Contacts
Public ContactB.A. Lemkes
Dept. of Internal Medicine, Academic Medical Centre
Outcome results
None listed